2025
Loss of GATA2 Promotes Invasion and Predicts Cancer Recurrence and Survival in Uterine Serous Carcinoma
Polaki U, Gilpin T, Patil A, Chiu E, Baker R, Liu P, Pavletich T, Seifi M, Mañán-Mejías P, Morrissey J, Port J, Schwartz R, Ong I, El-Rayes D, Khalifa M, Hui P, Horner V, Virumbrales-Muñoz M, Erickson B, Barroilhet L, McGregor S, Bresnick E, Matson D. Loss of GATA2 Promotes Invasion and Predicts Cancer Recurrence and Survival in Uterine Serous Carcinoma. JCI Insight 2025, 10: e187073. PMID: 40168074, PMCID: PMC12128953, DOI: 10.1172/jci.insight.187073.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaTreatment-related morbidityStudent's t-testSerous carcinomaAdjuvant chemotherapyPrimary uterine serous carcinomaUterine serous carcinoma cellsIncreased invasiveness in vitroStage I USCRecurrence-free survivalCox proportional hazard ratiosCancer-related survivalDepartment of ObstetricsKaplan-Meier methodFisher's exact testDepartment of PathologyProportional hazard ratiosRisk-stratified approachPersonalized medicine approachPredicting cancer recurrenceConfirmatory Western blotT-testClinicopathological metricsRecurrence-freeAmerican Cancer Society
2023
Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors
Schrank T, Kothari A, Weir W, Stepp W, Rehmani H, Liu X, Wang X, Sewell A, Li X, Tasoulas J, Kim S, Yarbrough G, Xie Y, Flamand Y, Marur S, Hayward M, Wu D, Burtness B, Anderson K, Baldwin A, Yarbrough W, Issaeva N. Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2216532120. PMID: 37523561, PMCID: PMC10410762, DOI: 10.1073/pnas.2216532120.Peer-Reviewed Original ResearchConceptsNF-κB-related genesEstrogen receptor alpha expressionDeintensification of therapyTreatment-related morbidityTumor-infiltrating CD4Receptor alpha expressionHPV carcinogenesisRadiosensitization of headOncogenic subtypesPIK3CA alterationsHNSCC tumorsPatient outcomesNeck tumorsT cellsTreatment responseHNSCC cellsTherapeutic intensityAtypical featuresIndependent cohortAlpha expressionNF-κBActive tumorTNF receptorTumorsPatient data
2021
Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria
Hoppe BS, Advani R, Milgrom SA, Bakst RL, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Mansur DB, Metzger ML, Pinnix CC, Plastaras JP, Roberts KB, Smith SM, Terezakis SA, Kirwan JM, Constine LS. Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 36-44. PMID: 33774076, DOI: 10.1016/j.ijrobp.2021.03.035.Peer-Reviewed Original ResearchConceptsPrimary mediastinal B-cell lymphomaMediastinal B-cell lymphomaB-cell lymphomaPET/CT responsePositron emission tomographyCell lymphomaDeauville scaleRadiation therapyCT responseAmerican Radium Society Appropriate Use CriteriaLong-term treatment-related morbiditySystematic reviewTreatment-related morbidityConsolidative radiation therapyAppropriate use criteriaEvidence-based guidelinesNon-Hodgkin lymphomaMeta-Analyses (PRISMA) guidelinesPreferred Reporting ItemsChemoimmunotherapy strategiesCurable subtypeAdditional therapyChemoimmunotherapy regimensRefractory diseasePediatric oncologistsDual activating FGFR1 mutations in pediatric pilomyxoid astrocytoma
Fomchenko EI, Reeves BC, Sullivan W, Marks AM, Huttner A, Kahle KT, Erson‐Omay E. Dual activating FGFR1 mutations in pediatric pilomyxoid astrocytoma. Molecular Genetics & Genomic Medicine 2021, 9: e1597. PMID: 33448156, PMCID: PMC8077124, DOI: 10.1002/mgg3.1597.Peer-Reviewed Original ResearchConceptsPilomyxoid astrocytomaPediatric patientsVariant allele frequencyHypothalamic/chiasmatic regionPathologic tissue diagnosisTreatment-related morbidityHigh recurrence ratePI3K/mTOR inhibitionYears of ageExome sequencing resultsSimilar time pointsWhole exome sequencing resultsHypothalamic dysfunctionClinical presentationSurgical managementRecurrence rateShorter survivalAggressive subtypeVision lossChiasmatic regionTissue diagnosisPatient tumorsRadiation therapyFGFR inhibitorsFGFR1 mutations
2019
Complications associated with immunotherapy for brain metastases.
Tran TT, Jilaveanu LB, Omuro A, Chiang VL, Huttner A, Kluger HM. Complications associated with immunotherapy for brain metastases. Current Opinion In Neurology 2019, 32: 907-916. PMID: 31577604, PMCID: PMC7398556, DOI: 10.1097/wco.0000000000000756.Peer-Reviewed Original ResearchConceptsBrain metastasesNeurologic toxicityImmune therapyPhase 2 clinical trialCheckpoint inhibitor therapyImmune checkpoint inhibitorsMultiple phase 2 clinical trialsTreatment-related morbidityBrain metastatic diseaseSymptomatic edemaCheckpoint inhibitorsAdverse eventsDurable responsesMedian survivalMetastatic diseaseInhibitor therapyMore patientsIntracranial activityPatient groupRadiation necrosisClinical trialsTherapy trialsMultidisciplinary teamMetastasisPatientsPoint/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?
Wirth LJ, Burtness B, Nathan CO, Grégoire V, Richmon J. Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How? American Society Of Clinical Oncology Educational Book 2019, 39: 364-372. PMID: 31099643, DOI: 10.1200/edbk_238315.Peer-Reviewed Original ResearchConceptsDe-escalate treatmentOropharyngeal carcinomaHPV-positive oropharyngeal carcinomaNeck cancer clinical researchNew systemic agentsPhase II trialPhase III trialsTreatment-related morbidityHigh cure ratesCancer clinical researchConcurrent cisplatinII trialOropharynx cancerPrimary surgeryDose intensityIII trialsInstitutional seriesInvasive resectionMultimodality treatmentSystemic agentsSystemic therapyPrimary diseaseCure rateToxic therapiesMultimodality strategy
2015
Human Papillomavirus–Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials
Bhatia A, Burtness B. Human Papillomavirus–Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials. Journal Of Clinical Oncology 2015, 33: 3243-3250. PMID: 26351343, PMCID: PMC5814107, DOI: 10.1200/jco.2015.61.2358.Peer-Reviewed Original ResearchConceptsClinical trialsRisk groupsHuman papillomavirus-associated oropharynx cancerHPV-negative OPCPoor-risk subsetTreatment-related morbidityDe-escalation trialsPrognostic risk groupsClinical trial optionsYounger median ageNew treatment strategiesIdeal patient groupNovel therapeutic targetInvasive surgical techniquesDeintensification trialsTreatment deintensificationOropharynx cancerSmoking exposureMetastatic diseaseModality therapyFavorable prognosisMedian ageBetter prognosisSuperior prognosisIntense therapy
2012
Short-Term Outcomes of Ablation Therapy for Hepatic Tumors: Evidence from the 2006–2009 Nationwide Inpatient Sample
Fox JP, Gustafson J, Desai MM, Hellan M, Thambi-Pillai T, Ouellette J. Short-Term Outcomes of Ablation Therapy for Hepatic Tumors: Evidence from the 2006–2009 Nationwide Inpatient Sample. Annals Of Surgical Oncology 2012, 19: 3677-3686. PMID: 22588470, DOI: 10.1245/s10434-012-2397-0.Peer-Reviewed Original ResearchConceptsProcedure-specific complicationsNationwide Inpatient SampleMetastatic liver tumorsOpen surgical approachHepatic tumorsPostoperative complicationsSurgical approachInpatient SampleLiver tumorsMultivariable logistic regression analysisTreatment-related morbidityCases/yearLogistic regression analysisResultsMost patientsTransfusion requirementsHospital morbidityAdverse eventsIntraoperative bleedingBackgroundRadiofrequency ablationHeart failureHepatic failurePatient factorsTerm outcomesLaparoscopic proceduresAblation therapy
2010
Biochemical and clinical responses after treatment of a catecholamine‐secreting glomus jugulare tumor with gamma knife radiosurgery
Castrucci WA, Chiang VL, Hulinsky I, Knisely JP. Biochemical and clinical responses after treatment of a catecholamine‐secreting glomus jugulare tumor with gamma knife radiosurgery. Head & Neck 2010, 32: 1720-1727. PMID: 19787788, DOI: 10.1002/hed.21242.Peer-Reviewed Original ResearchConceptsGlomus jugulare tumorsGamma knife radiosurgeryJugulare tumorsKnife radiosurgeryFunctional capacitySingle-fraction gamma knife radiosurgeryTumor growthMinimal treatment-related morbidityPrimary radiation therapyTreatment-related morbiditySignificant symptomatic improvementLocal tumor growthCatecholamine blockadeHypertensive crisisSymptomatic improvementClinical responseCatecholamine levelsPharmacologic blockadeRadiation therapyDurable controlRadiosurgeryBlockadeTumorsTreatmentMorbidity
1976
Treatment of hodgkin's disease using intensive chemotherapy followed by irradiation
Kun L, Devita V, Young R, Johnson R. Treatment of hodgkin's disease using intensive chemotherapy followed by irradiation. International Journal Of Radiation Oncology • Biology • Physics 1976, 1: 619-626. PMID: 824248, DOI: 10.1016/0360-3016(76)90143-7.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseResidual Hodgkin's diseaseTreatment-related morbidityUntreated Hodgkin's diseaseNormal tissue reactionsIntensive chemotherapyMarginal recurrenceCombination chemotherapyIncreased incidenceAutopsy examinationRadiation therapyTherapeutic efficacyFull doseMedical CollegeDiseasePatientsTissue reactionChemotherapyMarked enhancementIrradiation fieldMorbidityComplicationsRecurrenceTherapyIncidence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply